Microbleeds in Alzheimer Disease Are More Related to Cerebral Amyloid Angiopathy than Cerebrovascular Disease

2006 ◽  
Vol 22 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Yuriko Nakata-Kudo ◽  
Toshiki Mizuno ◽  
Kei Yamada ◽  
Kensuke Shiga ◽  
Kenji Yoshikawa ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Cerebrovascular Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid

Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis

2019 ◽  
Vol 79 (7) ◽  
pp. 716-737 ◽  
Author(s):  
María Carmona‐Iragui ◽  
Laura Videla ◽  
Alberto Lleó ◽  
Juan Fortea
Keyword(s):  
Down Syndrome ◽  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid

scholarly journals Characteristics of Aquaporin Expression Surrounding Senile Plaques and Cerebral Amyloid Angiopathy in Alzheimer Disease

2012 ◽  
Vol 71 (8) ◽  
pp. 750-759 ◽  
Author(s):  
Akihiko Hoshi ◽  
Teiji Yamamoto ◽  
Keiko Shimizu ◽  
Yoshikazu Ugawa ◽  
Masatoyo Nishizawa ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Senile Plaques ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid

P2-168: Screening for Serum Biomarkers for Cerebral Amyloid Angiopathy and Alzheimer Disease: Results from a Discovery Assay of 65 Cytokines

2016 ◽  
Vol 12 ◽  
pp. P680-P680
Author(s):  
Janka Hegedus ◽  
Ana Alvarez-Veronesi ◽  
Angela Zwiers ◽  
Anna Charlton ◽  
Ramnik Sekhon ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Serum Biomarkers ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid

scholarly journals Late-Life Vascular Risk Score in Association With Postmortem Cerebrovascular Disease Brain Pathologies

Stroke ◽  
2021 ◽  
Author(s):  
Shahram Oveisgharan ◽  
Lei Yu ◽  
Ana Capuano ◽  
Zoe Arvanitakis ◽  
Lisa L. Barnes ◽  
...  
Keyword(s):  
Cerebrovascular Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Risk Score ◽  
Odds Ratio ◽  
Amyloid Angiopathy ◽  
Individual Level ◽  
Framingham Risk ◽  
Increased Risk ◽  
Cerebral Amyloid ◽  
The Individual

Background and Purpose: The general cardiovascular Framingham risk score (FRS) identifies adults at increased risk for stroke. We tested the hypothesis that baseline FRS is associated with the presence of postmortem cerebrovascular disease (CVD) pathologies. Methods: We studied the brains of 1672 older decedents with baseline FRS and measured CVD pathologies including macroinfarcts, microinfarcts, atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. We employed a series of logistic regressions to examine the association of baseline FRS with each of the 5 CVD pathologies. Results: Average age at baseline was 80.5±7.0 years and average age at death was 89.2±6.7 years. A higher baseline FRS was associated with higher odds of macroinfarcts (odds ratio, 1.10 [95% CI, 1.07–1.13], P <0.001), microinfarcts (odds ratio, 1.04 [95% CI, 1.01–1.07], P =0.009), atherosclerosis (odds ratio, 1.07 [95% CI, 1.04–1.11], P <0.001), and arteriolosclerosis (odds ratio, 1.04 [95% CI, 1.01–1.07], P =0.005). C statistics for these models ranged from 0.537 to 0.595 indicating low accuracy for predicting CVD pathologies. FRS was not associated with the presence of cerebral amyloid angiopathy. Conclusions: A higher FRS score in older adults is associated with higher odds of some, but not all, CVD pathologies, with low discrimination at the individual level. Further work is needed to develop a more robust risk score to identify adults at risk for accumulating CVD pathologies.

Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab

Stroke ◽  
2021 ◽  
Author(s):  
Lukas Sveikata ◽  
Andreas Charidimou ◽  
Anand Viswanathan
Keyword(s):  
Clinical Trials ◽  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Β ◽  
High Rate ◽  
Amyloid Angiopathy ◽  
Cerebrovascular Pathology ◽  
Cerebral Amyloid

We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.

scholarly journals Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment

Neurology ◽  
2020 ◽  
Vol 95 (10) ◽  
pp. e1333-e1340 ◽  
Author(s):  
Aaron R. Switzer ◽  
Ikreet Cheema ◽  
Cheryl R. McCreary ◽  
Angela Zwiers ◽  
Anna Charlton ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Response Amplitude ◽  
Cerebrovascular Reactivity ◽  
White Matter Hyperintensity ◽  
Amyloid Angiopathy ◽  
Bold Response ◽  
Cerebral Amyloid

ObjectiveTo assess cerebrovascular reactivity in response to a visual task in participants with cerebral amyloid angiopathy (CAA), Alzheimer disease (AD), and mild cognitive impairment (MCI) using fMRI.MethodsThis prospective cohort study included 40 patients with CAA, 22 with AD, 27 with MCI, and 25 healthy controls. Each participant underwent a visual fMRI task using a contrast-reversing checkerboard stimulus. Visual evoked potentials (VEPs) were used to compare visual cortex neuronal activity in 83 participants. General linear models using least-squares means, adjusted for multiple comparisons with the Tukey test, were used to estimate mean blood oxygen level–dependent (BOLD) signal change during the task and VEP differences between groups.ResultsAfter adjustment for age and hypertension, estimated mean BOLD response amplitude was as follows: CAA 1.88% (95% confidence interval [CI] 1.60%–2.15%), AD 2.26% (1.91%–2.61%), MCI 2.15% (1.84%–2.46%), and control 2.65% (2.29%–3.00%). Only patients with CAA differed from controls (p = 0.01). In the subset with VEPs, group was not associated with prolonged latencies or lower amplitudes. Lower BOLD amplitude response was associated with higher white matter hyperintensity (WMH) volumes in CAA (for each 0.1% lower BOLD response amplitude, the WMH volume was 9.2% higher, 95% CI 6.0%–12.4%) but not other groups (p = 0.002 for interaction) when controlling for age and hypertension.ConclusionsMean visual BOLD response amplitude was lowest in participants with CAA compared to controls, without differences in VEP latencies and amplitudes. This suggests that the impaired visual BOLD response is due to reduced vascular reactivity in CAA. In contrast to participants with CAA, the visual BOLD response amplitude did not differ between those with AD or MCI and controls.

scholarly journals Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy

2006 ◽  
Vol 65 (10) ◽  
pp. 1012-1021 ◽  
Author(s):  
James Scott Miners ◽  
Zoë Van Helmond ◽  
Katy Chalmers ◽  
Gordon Wilcock ◽  
Seth Love ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid ◽  
Expression And Activity

scholarly journals Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease

2005 ◽  
Vol 64 (7) ◽  
pp. 588-594 ◽  
Author(s):  
Sarah B Domnitz ◽  
Elissa M Robbins ◽  
Alex W Hoang ◽  
Monica Garcia-Alloza ◽  
Bradley T Hyman ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Transgenic Mouse ◽  
Mouse Models ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Transgenic Mouse Models ◽  
Cerebral Amyloid
Sign in / Sign up

Export Citation Format

Share Document